Novo vs. KBP: How a $1.3B deal turned into an international legal fight
ESMO AstraZeneca
Biotech

ESMO: AstraZeneca data ‘validate’ focus on in-house ADCs

Europe’s leading cancer conference may be swimming in ADC data, but AstraZeneca remains convinced its in-house pipeline sets the pharma apart.
James Waldron Oct 18, 2025 12:55pm
ESMO Berlin 2025

ESMO: Roche wants oral SERD to benefit ‘all comers’

Oct 18, 2025 1:00am
Heat red cracked ground texture burning after volcano eruption Molten active lava texture background

Xoma and Lava buyout cools with lower offer

Oct 17, 2025 2:35pm
vials vaccine research vaccines factory manufacturing

Evaxion stock slips on phase 2 cancer vax data

Oct 17, 2025 2:07pm
weight loss from cancer

ESMO: Pfizer sees year-long weight gain in cancer patients

Oct 17, 2025 12:45pm
graphic art of a right hand signing something

Hansoh, Chugai ink separate and lucrative licensing agreements

Oct 17, 2025 11:04am
More News

Astellas turns down option to license Taysha gene therapy—again

Oct 17, 2025 10:50am

I-Mab unveils new name, strategy, asset and Hong Kong IPO plans

Oct 17, 2025 10:45am

ESMO: BMS believes ADC data allow it to 'stay ahead' of rivals

Oct 17, 2025 10:30am

Unpacking the FDA transparency push on CRLs

Oct 17, 2025 9:41am